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Abstract
A 45-year-old white male presented to our department with postoperative recurrence of
gastrointestinal poorly differentiated neuroendocrine carcinoma manifesting as lymph node
dissemination and a solitary implantation metastasis in the rectovesical pouch. Following disease
progression on chemotherapy, the patient was treated with radiotherapy using either a
conventional daily treatment or an accelerated hyperfractionated protocol to separate sites of
disease progression. Using serial CT scan assessment, changes in cross-sectional area of the
separately treated metastatic lesions were evaluated for determination of therapy response. The
accelerated hyperfractionated radiotherapy appeared to limit the rate of tumor growth to a greater
degree than the conventional fractionation schedule. Of uttermost importance, in this palliative
setting, the patient completed the intensified radiotherapy regimens with acceptable acute toxicity.
Given the proliferative capacity of poorly differentiated neuroendocrine carcinomas of the
gastrointestinal tract, radiotherapy may be a therapeutic supplement to chemotherapy, which
represents the main treatment option in this tumor entity. Importantly, tumors with a capacity for
rapid proliferation and regeneration may be particularly sensitive to the use of intensified
fractionation protocols in clinical radiotherapy.
Findings
Radiotherapy is typically administered by fractionated
schedules to allow normal tissue recovery from sublethal
damage between each treatment fraction. However, sur-
viving tumor cells also proliferate during the interfraction
periods, and in addition, accelerated repopulation is a rec-
ognized contributor to treatment failure. The rate of
repopulation often increases with time during radiother-
apy treatment, and accelerated fractionation protocols
have therefore been suggested as potentially advantageous
by shortening the overall treatment time [1]. Moreover,
hyperfractionated accelerated schedules, using a lower
dose per fraction combined with an increased number of
fractions and shortened overall treatment time, may also
improve tumor control. The radiobiological principles of
altered fractionation schedules, treatment time, and total
dose have been most extensively tested in clinical trials on
head-and-neck squamous cell carcinoma [2,3].
Undifferentiated small-cell carcinoma of the gastrointesti-
nal tract represents a rare tumor entity and may originate
in any site within the gastrointestinal tract. Most patients
either present with or rapidly develop disseminated dis-
ease. Traditionally, surgery has been a significant treat-
ment option in locoregionally limited disease, although
many patients ultimately have systemic relapse. These
tumors are generally highly sensitive to chemotherapy,
but in extensive disease, responses to chemotherapy are
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therapy is often aggressive [4]. Available data on clinical
situations for which radiotherapy may be of benefit, is
principally as part of the management of patients with
limited-stage disease of the esophagus, stomach, or rec-
tum [4,5].
A 45-year-old white male, never-smoker, presented to a
local hospital with a 1-month history of intermittent
bleedings per rectum. His medical background was unre-
markable. Lower endoscopy revealed an ulcer in the ter-
minal ileum adjacent to the ileocecal valve, and the
patient proceeded to resection of the terminal ileum and
right hemicolon. Histological examination (See addi-
tional file 1: Histology of the primary tumor surgical spec-
imen) confirmed a transmural small-cell carcinoma
containing nests of abnormal tubular and glandular struc-
tures, associated with vessel invasion, abundant in mitotic
figures and with high Ki67 proliferation index (90%), and
showing immunohistochemical positivity for synapto-
physin and chromogranin and lymph node involvement,
consistent with a poorly differentiated neuroendocrine
carcinoma of the gastrointestinal tract [6,7].
The patient was referred to our department four months
after the abdominal surgery when abdominal-pelvic CT
scanning had revealed an enlarged, retroperitoneal lymph
node (16 mm × 18 mm in the transverse view) located
between the abdominal aorta and inferior vena cava and
a lesion with peripheral contrast enhancement and
decreased central density (19 mm × 32 mm in the trans-
verse view) located in the rectovesical pouch. Because of
waiting time until admittance, a new CT scan was per-
formed (51 days after the previous, which was defined as
the day of disease relapse), confirming an additional ≥ 2-
fold increases of cross-sectional lesion area (Figure 1). The
patient proceeded to ultrasound-guided biopsy confirma-
tion of the retroperitoneal nodal relapse prior to com-
mencing chemotherapy consisting of etoposide (100 mg/
m2 daily, on days 1–3) and cisplatin (45 mg/m2 daily, on
days 2–3) in 4-week cycles (Figure 1; EP: etoposide/cispl-
atin). CT evaluation of tumor response was initially per-
formed after every two treatment cycles. Both pathologic
lesions showed significant initial responses; however, dis-
ease progression was noted at the retroperitoneal region
after the sixth cycle (Figure 1), resulting in discontinua-
tion of the etoposide/cisplatin chemotherapy. Following
additional CT evidence of disease progression (266 days
after the diagnosis of disease relapse), the patient pro-
ceeded to second-line temozolomide chemotherapy,
according to clinical experience from Uppsala University
Hospital in Sweden [8]; however, both the retroperitoneal
and the pelvic lesions progressed on this treatment (Figure
1; tem: temozolomide).
Given the insensitivity to chemotherapy, the patient was
assessed for palliative radiotherapy to facilitate pain con-
trol at the retroperitoneal site (See additional file 2:
Abdominal CT scan 364 days after the diagnosis of disease
relapse). To take account of the high proliferation index
noted in the initial and repeat biopsy specimens, a hyper-
fractionated accelerated protocol was considered to be of
therapeutic benefit. Provided a tolerance of 50 Gy with
conventional fractionation (2 Gy daily) for the spinal cord
and intestines, if one-third of the small bowel is exposed,
and an α/β ratio of 3 for these tissues, 37 fractions of 1.5
Gy might be tolerated. Hence, the patients proceeded to a
treatment schedule of 48 Gy delivered in 16 treatment
days with twice daily fractionation, using anterior-poste-
rior radiation fields (Figure 1; RT TV1: radiotherapy, target
volume 1). An abdominal-pelvic CT scan at two months
after completion of the radiotherapy (474 days after the
diagnosis of disease relapse) showed disease stabilization
at the retroperitoneal site (Figure 1).
Following the retroperitoneal radiation course, the
patient experienced voiding difficulties, consistent with
pelvic disease progression with tumor extension to the
seminal vesicles and the anterior rectal wall shown on the
CT scan, and additional MRI confirmed tumor infiltration
at the prostatic urethral lobe and posterior bladder wall
(See additional file 3: Pelvic MRI examination 492 days
after the diagnosis of disease relapse). Additional disease
progression was noted in the left supraclavicular fossa. A
trial of repeat etoposide/cisplatin chemotherapy was com-
menced; however, disease progression was noted and the
disease was deemed to be refractory to chemotherapy
(Figure 1; EP: etoposide/cisplatin).
Further radiotherapy to the two sites of progressive disease
was considered with the goals of symptom control and
disease constraints. The macroscopic pelvic tumor was
treated using a conventional fractionation protocol to a
total dose of 50 Gy (2 Gy in daily fractions) using ante-
rior-posterior radiation fields (Figure 1; RT TV2: radiother-
apy, target volume 2). However, at treatment completion,
the patient could no longer control micturition or defeca-
tion, which was clinically interpreted as pelvic disease
progression. The supraclavicular lymph node metastases
were subsequently treated using a CT-planned approach
to 51 Gy using a hyperfractionated accelerated protocol
(1.5 Gy twice daily fractionation in 17 treatment days)
(Figure 1; RT TV3: radiotherapy, target volume 3).
Towards the end of this treatment, the patient experienced
Common Toxicity Criteria Grade 1 pharyngeal toxicity.
Repeat CT examination (646 days after the diagnosis of
disease relapse) confirmed disease progression at the pel-
vic site, whereas a mixed response, in part with disease sta-
bilization, was observed at the supraclavicular site (Figure
1). This pattern of differential response was documentedPage 2 of 5
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months after the primary surgery.
Given that nodal tumor masses are regular ovoid struc-
tures that show proportional changes in all dimensions,
measurements of bidimensional tumor size (cross-sec-
tional area) are fully in accordance with volumetric meas-
urements when assessing treatment response [9].
Moreover, when almost all tumor cells are actively divid-
ing, as in this patient, it is conceivable that any change in
tumor size after a given treatment may be a direct conse-
quence of the clonogenic regeneration rate, and it may
therefore be possible to compare the efficacy of different
radiotherapy fractionation regimens. These considera-
tions are contingent on radiologic evaluation by a single
imaging modality. In this patient, MRI was done once (to
visualize intrapelvine structures; for practical reasons, cer-
vical MRI was done simultaneously). Compared with CT
scans, the MRI examination probably overestimated
tumor sizes.
In extrapulmonary small-cell carcinomas, no randomized
trials are reported to guide patient management, and few
data exists on patient outcome after radiotherapy. Given
the rarity of these tumor entities, treatment approaches
have typically been extrapolated from trials designed for
limited-stage small-cell lung carcinoma [10,11]. As out-
lined in a recent review, radiotherapy for small-cell carci-
noma of the gastrointestinal tract has been prescribed in a
wide variety of doses, ranging between 30 and 66 Gy, the
Poorly differentiated neuroendocrine carcinoma – progression and therapy response of disease manifestationsFigure 1
Poorly differentiated neuroendocrine carcinoma – progression and therapy response of disease manifesta-
tions. Repeated helical CT scannings were accomplished in the course of the disease relapse (when the patient was referred 
to our institution), which was defined as day 1. On the basis of the diagnostic description of contrast-enhancing lesions in the 
transverse view, cross-sectional area (the maximum diameter multiplied by perpendicular bisector) of each lesion was calcu-
lated, according to the established World Health Organization criteria for evaluation of tumor response to cytotoxic therapy. 
Filled circles: lesion size at each CT record, determined relative to the cross-sectional area at first appearance (set to the value 
of 1). Stars: the radiological review at day 492, done by MRI. Thick lines: duration of the therapy regimens. Arrowheads: time 
for start of chemotherapy cycles. EP: chemotherapy consisting of etoposide and cisplatin. tem: chemotherapy consisting of 
temozolomide. RT: radiotherapy. TV1: target volume 1 (pathologic retroperitoneal lymph nodes). TV2: target volume 2 (mac-
roscopic pelvic tumor). TV3: target volume 3 (pathologic supraclavicular lymph nodes).
days after disease relapse
0 100 200 300 400 500 600 700 800
re
la
tiv
e
 
cr
o
ss
-s
e
ct
io
n
a
l a
re
a
0
5
10
15
0
5
10
15
0
5
TV1
RT
tem EPEP
•
•
••
••••
••••
retroperitoneal lesion,
primary
•
••
•
•
•
•
retroperitoneal
lesion,
secondary
•
• •
••
•retroperitoneal
lesion,
tertiary
days after disease relapse
0 100 200 300 400 500 600 700 800
re
la
tiv
e
 
cr
o
ss
-s
e
ct
io
n
a
l a
re
a
0
5
10
15
0
5
0
0
5
5
tem EPEP
TV2 TV3
RT
•••
•
•
•• •
•
•
•
•
•
lesion in
rectovesical pouch
•
•• • •
supraclavicular lesion,
primary
•
•
•
•
supraclavicular lesion,
secondary
•
•
•
•
mediastinal lesions
(subcarinal, retrocrural)Page 3 of 5
(page number not for citation purposes)
Radiation Oncology 2008, 3:13 http://www.ro-journal.com/content/3/1/13higher doses typically administered with chemotherapy
and with curative intent [4]. In a recent retrospective, sin-
gle-center study on the use of radiotherapy in limited-
stage extrapulmonary small-cell carcinoma, only 2 of 18
reported patients had been treated with hyperfractionated
protocols [12]. The clinical observations in this patient
and a previously reported case [6] suggest a role for radia-
tion also with clearly palliative indications in extensive
gastrointestinal tract small-cell carcinoma.
In this patient, the independent courses of accelerated
hyperfractionated radiotherapy to the retroperitoneal and
supraclavicular nodal sites appeared to result in a greater
degree of tumor control when compared to the conven-
tional daily fractionation course delivered to the pelvic
recurrence. The 2-Gy Biological Equivalent Dose delivered
by the intensified fractionation schedules equals 44–48
Gy, and the patient was able to complete both of the
intensified radiotherapy regimens with acceptable acute
toxicity. This aspect, together with the advantage of a
reduction in overall treatment time, are critically impor-
tant objectives of optimized radiation oncology care in
the palliative therapy setting.
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Additional file 1
Histology of the primary tumor surgical specimen. The figure is dis-
played in PDF format. The panels represent sections with hematoxylin and 
eosin staining (left column) or immunohistochemical staining for Ki67 
(right column) and depict an ileal, transmural small-cell carcinoma con-
taining nests of abnormal tubular and glandular structures and with a 
high fraction (90%) of Ki67-positive tumor cells.
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717X-3-13-S1.pdf]
Additional file 2
Abdominal CT scan 364 days after the diagnosis of disease relapse. 
The figure is displayed in PDF format. The images were generated by mul-
tislice CT technique (with the liver parenchyma in contrast-enhanced por-
tovenous phase), and the two representative images in transverse view 
(left) and reconstructed image in coronal view (right) display retroperito-
neal lymph node metastases (M) located between the abdominal aorta 
and inferior vena cava. The round structure located adjacent to the left 
kidney was a parapelvine cyst, which remained unaltered throughout the 
disease course.
Click here for file
[http://www.biomedcentral.com/content/supplementary/1748-
717X-3-13-S2.pdf]
Additional file 3
Pelvic MRI examination 492 days after the diagnosis of disease 
relapse. The figure is displayed in PDF format. The two representative MR 
images are oblique and T2-weighted and display the tumor (periphery 
indicated by arrows) located in the rectovesical pouch, infiltrating into the 
posterior wall of the bladder (B) and the urethral lobe of the prostate (P). 
Tumor extension to the anterior rectal wall was observed on an accompa-
nying CT scan.
Click here for file
[http://www.biomedcentral.com/content/supplementary/1748-
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